The Latest Breaking News from FDA

When a product gets banned, it often makes headlines. Whether it’s due to health concerns, political controversy, or public backlash, banned items tend to stir up emotions—and disappear overnight. But not all bans last forever. Over time, some items are quietly reformulated, relabeled, or simply reintroduced with little fanfare. Here…

The recalled fruit was sold at Sam’s Club stores in 42 states

The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S (NYSE:NVO) Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years of age and older with hemophilia A or B without inhibitors.

Loomer's purge machine.

On Thursday, the U.S. Food and Drug Administration approved LENZ Therapeutics, Inc.’s (NASDAQ:LENZ) VIZZ (aceclidine ophthalmic solution, previously known as LNZ100) 1.44%, the first and only FDA-approved aceclidine-based eye drop for presbyopia in adults.

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57.

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago.

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?

Justin Timberlake's health battle highlights the hidden symptoms of Lyme disease amid a sharp rise in 2025 US cases

Food manufacturers are masters of psychology, using clever language and design on their packaging to make products seem healthier than they are. This marketing technique, known as creating a “health halo,” tricks our brains into giving a food item a pass. We feel less guilty about consuming it, which often…

Loomer's latest victory.